By defining the role of VISTA in controlling Cxcl9:Spp1 ratio and modulating CD8+ T cell dynamics, this study positions VISTA inhibition as a promising strategy to reshape the TME and potentiate anti-tumor immunity in PDAC. This evidence concerns the gene CD8A and neoplasm.